These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 25014023)

  • 1. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
    Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
    Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
    Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
    J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of nucleosome dynamics in Huntington's disease.
    Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
    Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
    Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
    Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
    Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
    Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
    Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
    Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
    Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
    Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Zadori D; Vecsei L; Klivenyi P
    J Neural Transm (Vienna); 2009 Sep; 116(9):1079-86. PubMed ID: 19551467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
    Mievis S; Blum D; Ledent C
    Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased metabolism in the R6/2 mouse model of Huntington's disease.
    van der Burg JM; Bacos K; Wood NI; Lindqvist A; Wierup N; Woodman B; Wamsteeker JI; Smith R; Deierborg T; Kuhar MJ; Bates GP; Mulder H; Erlanson-Albertsson C; Morton AJ; Brundin P; Petersén A; Björkqvist M
    Neurobiol Dis; 2008 Jan; 29(1):41-51. PubMed ID: 17920283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
    Wang CE; Li S; Li XJ
    Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.